ArticleEClinicalMedicine2022

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial.

Yi Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.